Inhalation of high concentrations of hydrogen ameliorates liver ischemia/reperfusion injury through A2A receptor mediated PI3K-Akt pathway
Li He, Chen Ouyang, Ye Zhouheng, Zhang Rongjia, Hu Huijun, Zhang Ning, Huang Junlong, Liu Wenwu, Sun Xuejun · Biochemical Pharmacology · 2017
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Inhalation of high concentrations of hydrogen ameliorates liver ischemia/reperfusion injury through A2A receptor mediated PI3K-Akt pathway” is organized in H2HUBB under the research focus molecular hydrogen fatty liver study 2017. The publication is cited as Li He, Chen Ouyang, Ye Zhouheng, Zhang Rongjia, Hu Huijun, Zhang Ning, Huang Junlong, Liu Wenwu, Sun Xuejun, Biochemical Pharmacology, 2017. This animal study examined Inhalation of high concentrations of hydrogen ameliorates liver ischemia/reperfusion injury through A2A receptor mediated PI3K-Akt pathway. The abstract describes Mouse model; sample size 6. The abstract reports: Our findings indicate that HCH may protect the liver against I/R injury through the A dependent PI3K-Akt pathway. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen fatty liver study 2017 overview
This study explored the hepatoprotection of high concentrations of hydrogen (HCH) inhalation in a mouse hepatic ischemia/reperfusion (I/R) injury model and the potential mechanism. Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.
Study design and hydrogen intervention
Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Mouse model. Sample size: 6. Blinding: Unknown. Control status: Unknown.
Delivery method: Other or not reported.
Reported findings and scientific interpretation
For this molecular hydrogen fatty liver study 2017, the study record reports the following: The abstract reports: Our findings indicate that HCH may protect the liver against I/R injury through the A dependent PI3K-Akt pathway.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Preclinical animal findings may not translate directly to human outcomes.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.